# US 2022/0033462 A1 · Inhibitory chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033462 A1
- Document ID: US20220033462A1
- Status: Published application
- Kind: A1
- Application number: 17/385,805
- Filed: 2021-07-26
- Published: 2022-02-03
- Earliest claimed: 2014-11-12
- Assignees: Allogene Therapeutics, Inc.; Cellectis
- Applicants: Allogene Therapeutics, Inc.; Cellectis
- Inventors: ARVIND RAJPAL; Shobha Chowdary Potluri; Laurent Poirot; Alexandre Juillerat; Thomas Charles Pertel; Donna Marie Stone; Barbra Johnson Sasu
- Web page: https://patentgrep.com/patent/US20220033462A1

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4276: {Prostate specific membrane antigen [PSMA]}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12N 5/0636: {T lymphocytes}
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2239/21: Transmembrane domain
- A61K 2239/29: Multispecific CARs
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

## Claims

### Claim 1

A method for treating a patient in need thereof comprising: (a) providing an immune cell; and (b) administering said immune cell to said patient, wherein the immune cell comprises:
a first CAR comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and an intracellular domain; and
a second CAR comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and an intracellular domain, wherein:
the intracellular domain of the second CAR comprises an Immunoreceptor Tyrosine-based Switch Motif (ITSM), wherein said ITSM is a sequence of amino acids TX1YX2X3X4 (SEQ ID NO: 2049), wherein
X1 is E;
X2 is A or S;
X3 is S or E; and
X4 is V or I; and
the intracellular domain of the second CAR has at least 95% amino acid sequence identity with SEQ ID NO: 2016.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ITSM is selected from the group consisting of TEYASI (SEQ ID NO: 936), TEYSEI (SEQ ID NO: 940), and TEYSEV (SEQ ID NO: 941).

### Claim 3 (depends on 1)

The method of claim 1, wherein the antigen binding domain of the second CAR is a single chain variable fragment (scFv).

### Claim 4 (depends on 1)

The method of claim 1, wherein the intracellular domain of the second CAR is selected from the group consisting of SEQ ID NO: 2014, SEQ ID NO: 2015, and SEQ ID NO: 2016.

### Claim 5

A method of treating cancer, comprising administering an immune cell to a patient, wherein the immune cell comprises:
a first CAR comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and an intracellular domain; and
a second CAR, wherein the second CAR comprises:
an extracellular domain comprising an antigen binding domain,
a transmembrane domain, and
an intracellular domain, wherein:
the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif (ITSM), wherein said ITSM is a sequence of amino acids TX1YX2X3X4 (SEQ ID NO: 2049), wherein
X1 is E;
X2 is A or S;
X3 is S or E; and
X4 is V or I; and
the intracellular domain has at least 95% amino acid sequence identity with SEQ ID NO: 2016.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cell cancer, liver cancer, brain cancer, lymphoma, leukemia, or lung cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is lymphoma.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cancer is leukemia.

### Claim 9 (depends on 5)

The method of claim 5, wherein the ITSM is selected from the group consisting of TEYASI (SEQ ID NO: 936), TEYSEI (SEQ ID NO: 940), and TEYSEV (SEQ ID NO: 941).

### Claim 10 (depends on 9)

The method of claim 9, wherein the antigen binding domain of the second CAR is a single chain variable fragment (scFv).

### Claim 11 (depends on 10)

The method of claim 10, wherein the intracellular domain of the second CAR is selected from the group consisting of SEQ ID NO: 2014, SEQ ID NO: 2015, and SEQ ID NO: 2016.

### Claim 12 (depends on 6)

The method of claim 6, wherein the ITSM is selected from the group consisting of TEYASI (SEQ ID NO: 936), TEYSEI (SEQ ID NO: 940), and TEYSEV (SEQ ID NO: 941).

### Claim 13 (depends on 12)

The method of claim 12, wherein the antigen binding domain of the second CAR is a single chain variable fragment (scFv).

### Claim 14 (depends on 13)

The method of claim 13, wherein the intracellular domain of the second CAR is selected from the group consisting of SEQ ID NO: 2014, SEQ ID NO: 2015, and SEQ ID NO: 2016.
